Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations

scientific article published on 01 April 1984

Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID6607955

P50authorSteven RosenbergQ2347448
P2093author name stringEberlein TJ
Rosenstein M
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectimmunotherapyQ1427096
P304page(s)2117-2122
P577publication date1984-04-01
P1433published inJournal of ImmunologyQ3521441
P1476titleAdoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations
P478volume132

Reverse relations

cites work (P2860)
Q35603985A mouse tumor-specific transplantation antigen is a heat shock-related protein
Q37185460Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells
Q63965639Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2
Q49141356Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma
Q68299436Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy
Q46658506Correlation of tumor specific delayed type hypersensitivity reaction and tumor protection to SV40-induced mKSA fibrosarcoma
Q36355924FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens
Q39488901Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy
Q69054029In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line
Q67532362Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guérin nucleic acid fraction
Q41912662Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset
Q54992787Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.
Q33848587Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells
Q68907677The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice
Q44969922The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity
Q39550760The clinical potential of interleukin-2.
Q68915730The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice
Q55283530The roles of CD8+ and CD4+ cells in tumor rejection.
Q36350025Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells
Q67801959Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations

Search more.